Umiposgene parvec

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug NameUmiposgene parvec
Drug Alias NameCarfostinNAN-101AB-1002BNP116.sc-CMV.I1c
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/8 vector
Mechanisms of ActionProtein phosphatase 1 regulatory subunit gene transferenceProtein phosphatase 1 inhibitors
TargetsProtein phosphatase 1 regulatory subunitProtein phosphatase 1
Therapy Area/IndicationsMyocardial IschemiaHeart Failure, SystolicHeart Failure, Diastolic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAskBio IncBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesAskBio Inc
Inactive CompaniesBayer AG
Active IndicationsMyocardial IschemiaHeart Failure, SystolicHeart Failure, Diastolic +[5] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A